Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Action On Sexual Supplements Should Spur Better Self-Policing – UNPA

This article was originally published in The Tan Sheet

Executive Summary

The proliferation of erectile dysfunction "dietary supplements" adulterated with prescription drugs should lead the supplement industry to sharpen its capabilities to keep these illegal products off the market, United Natural Products Alliance President Loren Israelsen says
Advertisement

Related Content

Gaps In Spiked Supplement Net Could Shrink With Non-Targeted Screening
FDA Lifts Curtain On The Secret Behind Magic Power Coffee
FDA Lifts Curtain On The Secret Behind Magic Power Coffee
FDA Maintains Pressure Against Adulterated ED Supplements
ED supplement crackdown
“Promising” Trend: FDA Acts On Unapproved Drugs, Tainted Supplements
Sexual supplement recall
Canada warns against sex enhancement drug
Enzyte Marketer Berkeley Settles Complaints For $2.5 Mil.
Enzyte Marketer Berkeley Settles Complaints For $2.5 Mil.
Advertisement
UsernamePublicRestriction

Register

PS101295

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel